Intravenous infusion of glucose in patients with compensated nonischemic cardiovascular disease has demonstrated that the glucose disappearance slope, GK, is significantly lower than in normal subjects. Immunoassay of plasma insulin in 13 of these cardiac patients showed a reduced insulin response to hyperglycemia in the majority. All had a delayed decline of plasma insulin values.
SUMMARY
Intravenous infusion of glucose in patients with compensated nonischemic cardiovascular disease has demonstrated that the glucose disappearance slope, GK, is significantly lower than in normal subjects. Immunoassay of plasma insulin in 13 of these cardiac patients showed a reduced insulin response to hyperglycemia in the majority. All had a delayed decline of plasma insulin values. Plasma free fatty acids (FFA) were significantly elevated in the fasting state but were not significantly correlated with the reduced GK. During the acute hyperglycemia, plasma free fatty acid, potassium, and inorganic phosphate concentrations declined as in the normal subjects. Although cardiac index was reduced in most patients, a linear correlation with GK was not obtained.
To examine the possible role of enhanced sympathetic stimulation seen in cardiac patients, norepinephrine was infused into normal subjects during a glucose-tolerance test (GTT). A decline in glucose tolerance and plasma insulin was observed to levels approximating those seen in the cardiac patients, suggesting a neurohumoral mechanism for the glucose intolerance in cardiac patients. It would therefore appear that the glucose intolerance in compensated cardiac subjects with a reduced cardiac output is frequently an acquired rather than a genetically determined metabolic disorder. Additional Indexing Words: Glucose-tolerance test Free fatty acids Norepinephrine SIGNIFICANT reductions of glucose tolerance observed in many patients with clinical evidence of ischemic cardiovascular disease have suggested a close relationship of this disease to diabetes mellitus. ' following myocardial infarction, a secondary influence of such abnormalities on glucose tolerance may be operative, unrelated to the pathogenesis of the cardiac disorder. To evaluate this possibility, a study of glucose tolerance in cardiac patients without evidence of myocardial ischemia was undertaken. These patients had no symptoms, physical findings, or laboratory evidence of ischemic heart disease. Hemodynamic studies were performed in most of the subjects during cardiac catheterization, although coronary angiography was not done. No patient was included who had a history of obesity, diabetes mellitus, or a Each patient undergoing cardiac catheterization had duplicate determinations of cardiac index in the basal state by the indocyanine-green technique. No subject was in congestive heart failure or showed clinical evidence of nutritional deficiency at the time of study. All patients with cardiomyopathy had been hospitalized for at least 6 weeks prior to testing.
Hematocrit, serum albumin, SGOT, alkaline phosphatase, and bilirubin were normal in each subject. Despite a reduced salt intake in most patients serum sodium was normal in each, averaging 141 mEq/L. Presumably insulin secretion would not be affected, since only drastic reduction of extracellular sodium reduces hormone secretion.9 Half of the patients had been receiving thiazide diuretics, but these were interrupted at least 48 hours before study. All subjects were normokalemic and receiving digitalis. Three hundred grams of carbohydrate daily was given to all subjects for the 3 days prior to testing.
After an overnight fast without smoking, a percutaneous venous catheter was placed in a forearm vein, and glucose was given intravenously over 90 seconds in a dosage10 of 1 g/ Plasma immunoreactive insulin response to glucose load, 1 g/kg0 7, in normal subjects (limits shown in shaded area) and in patients with nonischemic cardiovascular disease. O 
16
'IO 1D kg°7. Blood samples were collected in EDTA during fasting at 2, 4, 6, and 10 minutes, and at 10-minute intervals thereafter for 1 hour followed by a single sample at 2 hours. Plasma was separated in a refrigerated centrifuge and stored in a freezer for subsequent analysis of glucose,' immunoreactive insulin,*12 free fatty acids,'3' 14 potassium,15 and inorganic phosphate. 16 A plot of glucose concentrations with time on semilogarithmic paper enabled derivation of a slope constant, GK, to estimate the disappearance rate of glucose from the vascular compartment in each patient.3 17 The slope was calculated from the glucose concentrations after 10 minutes, since the portion prior to this time is largely a reflection of the rapid distribution of glucose within the extracellular space.'8 A GK of 1.1 was considered the lower limit of normal, whereas GK between 0.9 and 1.1 was considered borderline, and below 0.9 definitely diabetic.3 ' 10 Results Because of the reported diminution of glucose tolerance in individuals over 50 years of age,19-21 patients were grouped into those below and above this age, each group containing 14 patients. The mean GK for the group of normal subjects approximates that found in other series,3 10, 20,22,23 ( fig. 1 ). The mean GK for the entire cardiac group of 28 falls clearly in the borderline range, with the group above age 50 slightly lower than the group below age 50. The mean GK for the above age 50 group was 0.99 (SE +0.08), and the mean GK for those under 50 years was 1.12 (sE+0.11), and were significantly below control values (P<0.006 for subjects below age 50). Approximately 6O in each cardiac group was abnormal. In addition, subdivision of patients into 20 to 39 and 40 to 49 age groups has revealed no significant differences in mean G,K ( Plasma potassium, inorganic phosphate, and free fatty acid responses to glucose load, 1 g/kg0 7.
Fasting free fatty acids were significantly higher (P < 0.02 for patients < 50, P < 0.01 for all patients) in nonischemic cardiovascular disease than in normal subjects. Means and standard errors are shown. in the cardiac group. Despite their exaggerated insulin responses, however, GK was less in each case than the mean of the normal group, indicating insulin insensitivity as a possible contributing factor. All cardiac patients had an elevated insulin/glucose ratio after 40 minutes. Figure 3 indicates fasting blood sugar as a function of GK. It is noteworthy that only seven of the patients had fasting hyperglycemia, as defined by a fasting blood sugar greater than 100 mg/100 ml. Consequently, fasting blood sugar alone was not a sensitive index of glucose intolerance, although the general correlation of decreasing fasting blood sugar with increasing GK was evident.
Serum potassium and phosphate each showed declines of approximately 10% within the first hour ( fig. 4 ). Although the initial decline in plasma phosphate was slightly greater in the patients with cardiovascular disease than in the normal group, the differences were not statistically significant for either potassium or phosphate.
Fasting plasma free fatty acids in the cardiac subjects were significantly higher than control. During the GTT, free fatty acids declined to levels comparable to those seen in the normal subjects, returning toward initial levels within 2 hours ( fig. 4 ). Since it has been proposed that glucose intolerance may be related to elevated plasma concentration of fasting free fatty acids,24 the relation of this substrate to GK was examined ( fig. 5 ). While the mean fasting free fatty acid level in the cardiac patients was significantly higher than in the normal group, more than half of those with reduced rates of glucose clearance had fasting free fatty acid levels within the normal range. Although elevated free fatty acid levels are seen in many cardiac patients, the plasma level of this substrate does not appear to be the primary determinant of glucose intolerance in this group.
To assess whether or not circulatory abnormalities may have contributed to the reduced glucose clearance, resting cardiac index was related to GK. In figure 6 , the shaded area represents the normal range for both GK and cardiac index, with the lower limits at 1.1 for GK and 2.6 L/min/m2 for the cardiac index. The patients with the lowest cardiac index showed the lowest values of GK. There were no evident differences in this regard between the different etiological forms of nonischemic cardiac disease included in this study. It has been shown that myocardial norepinephrine is reduced and urinary catecholamine excretion is increased in patients with moderate to severe heart disease, 25, 26 and this has been considered as evidence of enhanced sympathetic activity. Since the catecholamines can reduce insulin secretion by the pancreas,27 28 a neurohumoral mechanism may be responsible for the observed glucose intolerance. To evaluate the possible relation between norepinephrine and glucose intolerance, four normal volunteers were tested with glucose before and during infusions of norepinephrine, approximately 0.1 y/kg/min, with continuous arterial pressure monitoring, so that a diastolic rise of less than 10 mm Hg was maintained. Arterial sampling was used and the subjects were infused first in the basal state with glucose, then for 1 hour with norepinephrine alone, followed by a second identical glucose challenge during continued norepinephrine infusion. The studies of Streeten and associates, 22 indicated the normal response to repeated glucose challenge to be an increase in the glucose disappearance slope. However, our normal individuals showed a significant decline in GK to values comparable to those obtained in patients with cardiovascular disease ( fig. 7) . The decline in GK was accompanied by a diminution of plasma insulin response. During the norepinephrine infusion alone, FFA rose from 543 + 148 ,uEq/L to 1022 102 /cEq/L after 1 hour. Following the second glucose injection, FFA did not significantly change (815 180 ,uEq/L 1 hour after glucose), reflecting the opposing effects of norepinephrine and hyperglycemia.
Discussion
The high incidence of glucose intolerance in patients with valvular disease and cardiomyopathy correlates well with those values obtained by other investigators studying ischemic heart disease.3 4'6 These findings would suggest that reduced glucose tolerance in clinically evident cardiovascular disease is not necessarily related to the underlying etiology.
Some investigators have noted a progressive reduction in intravenous glucose tolerance with increasing age in normal sub-Circution, Volume XXXVIII, September 1968 [19] [20] [21] There is general agreement that this is so in the elderly, but below age 50 reports are conflicting. Wahlberg,3 in a series of 200 normal persons, could not demonstrate a reduced mean GK in those subjects below age 60. Dyck and Moorhouse23 also failed to show differences in normal subjects below age 50. Their data are even more impressive in that the high glucose dosage that they used (50 g/m2 BSA) would have been expected to make the test more sensitive. These observations agree with our own analysis by decade in the cardiac group, in which significant differences in mean GK were not observed. Thus, the influence of age as a determinant of GK in cardiac patients would appear to be of minor importance. In normal subjects pretreated with cortisone, a decadeby-decade reduction in glucose tolerance has been reported,29 but the precise mechanism and significance of this observation remain to be determined.
It is well known that inadequate nutrition or reduced carbohydrate intake may be responsible for glucose intolerance. All patients received 1 g sodium diets while in the hospital, and carbohydrate supplements were given for 3 days before testing. The subjects with cardiomyopathy, in particular, were treated for at least 6 weeks before testing. Oral glucose tolerance in heart failure may be reduced by malabsorption of the glucose or by hepatic congestion. 30 All patients had been treated maximally to minimize these factors, and intravenous glucose testing circumvented the problem of malabsorption.
Thiazide diuretics have been implicated in the aggravation of preexisting diabetes,31 and have recently been shown to cause glucose intolerance in some normal subjects after 6 months' use.32 None of the subjects had received the drug for the minimum period required to produce intolerance in normal persons. Thiazides were discontinued in those patients using them before study for at least 48 hours prior to testing, and most were thiazide-free for a week or more. GK values in those patients who had previously received thiazides were not significantly Circulation, Volume XXXVIII, September 1968 different from those seen in patients not taking these drugs. Plasma insulin levels have been shown to be elevated following oral glucose in ischemic heart disease.33'34 With intravenous testing, however, Nikkila and associates,34 found the insulin response to be lower than normal. Most of our subjects showed a reduced insulin response to intravenous glucose. A few had values greater than normal that continued throughout the test period. These latter patients are of particular interest in that their glucose disappearance rates are unusually slow for the amount of insulin present, suggesting a degree of insulin resistance (table 2). This was not related to obesity or hypertension, as these were not present in the subjects studied, but the elevated free fatty acid levels may be a contributing factor. The persistence of elevated plasma insulin after 30 minutes in all of our cardiac patients is presumably due to the persistence of hyperglycemia, and is amply demonstrated by the high insulin/glucose ratio after 40 minutes.
The demonstration of reduced glucose tolerance in cardiac patients with reduced cardiac output suggests that circulatory factors, such as the rate of delivery of glucose to the pancreas or its peak concentration, might be responsible. The transient diminution in glucose tolerance seen following acute myocardial infarction,2' 35-38 with gradual improvement during recovery,2' 37, 38 may be evidence for such circulatory factors. However, a linear correlation between cardiac index and glucose clearance was not obtained, and the time to peak glucose level, as well as for establishing a linear decline of substrate concentration, did not differ from normal. These suggest that other factors may participate to a greater extent than the circulatory status.
A direct neurohumoral effect on the pancreas in normal subjects was suggested by changes during norepinephrine infusion. Since changes in the tissue concentration and excretion of norepinephrine occur in moderate to advanced cardiac disease and not in asymptomatic patients,25' 26 it is possible that a sympathomimetic effect is operative in the presence of more severe disease. According to this view, the chronic reduction of cardiac output would establish some degree of enhanced sympathetic activity, which, by reducing insulin secretion, would serve as a basis for the diminished glucose tolerance observed in the majority of cardiac patients studied. The significance of glucose intolerance as a secondary response to cardiac disease is not known, but a reduced uptake of substrate by peripheral tissues may adversely affect metabolism in many organs.
